Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Framycetin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | RECQL | P46063 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | LRAT | O95237 | 1/20 | 0.89 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Framycetin SCHEMBL2133931 | 1.00 | BLM (0.98) | BLMRECQLTDP1MEN1LRAT | |
| Framycetin SCHEMBL3696748 | 1.00 | BLM (0.98) | BLMRECQLTDP1MEN1LRAT | |
| Framycetin SCHEMBL29628935 | 1.00 | BLM (0.98) | BLMRECQLTDP1MEN1LRAT | |
| Framycetin SCHEMBL2133938 | 1.00 | BLM (0.98) | BLMRECQLTDP1MEN1LRAT | |
| Framycetin SCHEMBL373681 | 1.00 | BLM (0.98) | BLMRECQLTDP1MEN1LRAT | |
| Paromomycin SCHEMBL3355 | 0.99 | BLM (1.00) | BLMRECQLTDP1MEN1LRAT | |
| Paromomycin SCHEMBL691558 | 0.99 | BLM (1.00) | BLMRECQLTDP1MEN1LRAT | |
| Paromomycin SCHEMBL2527138 | 0.99 | BLM (1.00) | BLMRECQLTDP1MEN1LRAT | |
| Paromomycin SCHEMBL1680052 | 0.99 | BLM (1.00) | BLMRECQLTDP1MEN1LRAT | |
| Framycetin SCHEMBL3037 | 0.97 | BLM (0.92) | BLMRECQLTDP1MEN1LRAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720311-A1 | TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260083665-A1 | IMPLANTABLE AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | PANTHER THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12508222-B2 | Implantable and biodegradable drug delivery devices and methods of use thereof | PanTher Therapeutics, Inc. | 2025-12-30 | — | — | US | disclosed |
| US-12437392-B2 | Mobile sensing system for crop monitoring | ADAVIV (US) | 2025-10-07 | — | — | US | disclosed |
| US-12329491-B2 | Method and system for augmented imaging in open treatment using multispectral information | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-06-17 | — | — | US | disclosed |
| US-12325646-B2 | Fertigation water treatment | UNIVERSITY OF GUELPH (CA) | 2025-06-10 | — | — | US | disclosed |
| EP-4558130-A1 | TISSUE PENETRATING AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | Panther Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12208160-B2 | Pharmaceutical compositions comprising coated API | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2025-01-28 | — | — | US | disclosed |
| US-20250024837-A1 | PESTICIDE SYSTEM | BANISH, MICHELE | 2025-01-23 | — | — | US | disclosed |
| US-20240397880-A1 | AERIAL MOBILE SENSING SYSTEM FOR CROP MONITORING | ADAVIV (US) | 2024-12-05 | — | — | US | disclosed |
| US-20100062067-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| CN-101583339-A | Compositions comprising macromolecular assemblies of lipid and surfactant | MALVERN COSMECEUTICS LTD (GB) | 2009-11-18 | — | — | CN | disclosed |
| EP-2099410-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | Malvern Cosmeceutics Limited (GB) | 2009-09-16 | — | — | EP | disclosed |
| CN-101475913-A | Special culture medium for separating phytophthora sojae | UNIV NORTHEAST AGRICULTURAL (CN) | 2009-07-08 | — | — | CN | disclosed |
| WO-2008065451-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| CN-101184473-A | Composition for use in the solubilisation of hydrophobic active agents | MALVERN COSMECEUTICS LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| EP-1890675-A1 | COMPOSITIONS COMPRISING A LIPID AND COPOLYMER OF STYRENE AND MALEIC ACID | Malvern Cosmeceutics Limited (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006129127-A1 | COMPOSITIONS COMPRISING A LIPID AND COPOLYMER OF STYRENE AND MALEIC ACID | MALVERN COSMECEUTICS LIMITED (GB) | 2006-12-07 | — | — | WO | disclosed |
| EP-0954327-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998000159-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083665-A1 | IMPLANTABLE AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | VEGFA, LDHA, FGF23 | BLM 4761/4885RECQL 4447/4885TDP1 2006/4885 |
| US-20250024837-A1 | PESTICIDE SYSTEM | ACHE, PFAS, FPGS | BLM 670/4885RECQL 1187/4885TDP1 100/4885 |
| US-20100062067-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | CLTB, APOB, ABCB4 | BLM 46/4885RECQL 1255/4885TDP1 2305/4885 |
| US-12508222-B2 | Implantable and biodegradable drug delivery devices and methods of use thereof | PIK3R2, ABCB1, PIK3R1 | BLM 1754/4885RECQL 1554/4885TDP1 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.